Cargando…
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
BACKGROUND: Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human colorectal cancer (CRC) previously treated with conventional chemotherapy would be sensitive to T-cell killing mediated by carcinoembryonic antigen (CEA)/CD3-bispecific...
Autores principales: | Osada, T, Hsu, D, Hammond, S, Hobeika, A, Devi, G, Clay, T M, Lyerly, H K, Morse, M A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813763/ https://www.ncbi.nlm.nih.gov/pubmed/19953093 http://dx.doi.org/10.1038/sj.bjc.6605364 |
Ejemplares similares
-
Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017) -
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
por: Ding, X, et al.
Publicado: (2009) -
TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population
por: Loebinger, M R, et al.
Publicado: (2010) -
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006) -
Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration
por: Thomas, Z I, et al.
Publicado: (2011)